Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delirium in patients with advanced cancer.

The Lancet. Oncology·2016
Same author

THE RISE OF THE CHIEF EXPERIENCE OFFICER.

Physician leadership journal·2015
Same author

Road To Developing Regulatory Pathway For Biologic Follow-ons Has Many Turns.

Biotechnology healthcare·2013
Same author

Approvals, FDA actions, clinical trials.

Biotechnology healthcare·2013
Same author

HCV testing cost-effective alternative to treating advanced disease.

Biotechnology healthcare·2013
Same author

Approvals, FDA actions, clinical trials.

Biotechnology healthcare·2013
Same journal

Big pharma moves into biologics.

Biotechnology healthcare·2013
Same journal

Study: High Copayments Cut Biodrug Use up to 21 Percent.

Biotechnology healthcare·2013
Same journal

Avian flu and the quest for immunity: not just chicken feed.

Biotechnology healthcare·2013
Same journal

Variety of Biotech Therapies, Uses Take Prominence Among ASCO Presentations.

Biotechnology healthcare·2013
Same journal

Opening the door to follow-on proteins?

Biotechnology healthcare·2013
Same journal

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnology healthcare·2013
See all related articles

Related Experiment Video

Updated: May 23, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

HER2 TESTS: How Do We Choose?

Bob Carlson

    Biotechnology Healthcare
    |April 6, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Accurate HER2 testing is crucial for effective breast cancer treatment. Incorrect results can lead to costly, ineffective therapies or deny life-saving options to patients.

    More Related Videos

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
    11:34

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

    Published on: December 5, 2017

    Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
    10:21

    Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

    Published on: December 25, 2017

    Related Experiment Videos

    Last Updated: May 23, 2026

    Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
    08:28

    Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

    Published on: May 9, 2025

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
    11:34

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

    Published on: December 5, 2017

    Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
    10:21

    Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

    Published on: December 25, 2017

    Area of Science:

    • Oncology
    • Medical Diagnostics

    Background:

    • Human Epidermal growth factor Receptor 2 (HER2) status is a critical biomarker in breast cancer.
    • Inaccurate HER2 testing is a recognized clinical challenge with significant implications.

    Purpose of the Study:

    • To highlight the clinical impact of erroneous HER2 test results.
    • To emphasize the need for improved diagnostic accuracy in HER2 testing.

    Main Methods:

    • Review of clinical guidelines and diagnostic standards for HER2 testing.
    • Analysis of the consequences of misdiagnosed HER2 status in breast cancer management.

    Main Results:

    • Incorrect HER2 test results are frequently encountered.
    • Misdiagnosis leads to suboptimal treatment selection, including unnecessary expenses and denial of beneficial therapies.

    Conclusions:

    • Ensuring accurate HER2 testing is paramount for optimal patient outcomes in breast cancer care.
    • Improved diagnostic accuracy can prevent financial waste and ensure appropriate patient access to targeted therapies.